Share-based Payment Arrangement, Expense of Adaptive Biotechnologies Corp from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Adaptive Biotechnologies Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • Adaptive Biotechnologies Corp Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $13,257,000, a 2% decline year-over-year.
  • Adaptive Biotechnologies Corp Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $51,595,000, a 8.4% decline year-over-year.
  • Adaptive Biotechnologies Corp annual Share-based Payment Arrangement, Expense for 2024 was $53,610,000, a 15% decline from 2023.
  • Adaptive Biotechnologies Corp annual Share-based Payment Arrangement, Expense for 2023 was $62,908,000, a 13% increase from 2022.
  • Adaptive Biotechnologies Corp annual Share-based Payment Arrangement, Expense for 2022 was $55,477,000, a 28% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Adaptive Biotechnologies Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $51,595,000 $13,257,000 -$265,000 -2% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $51,860,000 $13,359,000 +$401,000 +3.1% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $51,459,000 $12,147,000 -$2,151,000 -15% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $53,610,000 $12,832,000 -$2,724,000 -18% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $56,334,000 $13,522,000 -$1,814,000 -12% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $58,148,000 $12,958,000 -$4,387,000 -25% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $62,535,000 $14,298,000 -$373,000 -2.5% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $62,908,000 $15,556,000 +$1,262,000 +8.8% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $61,646,000 $15,336,000 +$1,194,000 +8.4% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $60,452,000 $17,345,000 +$3,165,000 +22% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $57,287,000 $14,671,000 +$1,810,000 +14% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $55,477,000 $14,294,000 +$2,419,000 +20% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $53,058,000 $14,142,000 +$2,499,000 +21% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $50,559,000 $14,180,000 +$2,931,000 +26% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $47,628,000 $12,861,000 +$4,377,000 +52% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $43,251,000 $11,875,000 +$4,632,000 +64% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q3 2021 $38,619,000 $11,643,000 +$5,173,000 +80% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $33,446,000 $11,249,000 +$4,876,000 +77% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $28,570,000 $8,484,000 +$3,809,000 +81% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $24,761,000 $7,243,000 +$3,832,000 +112% 01 Oct 2020 31 Dec 2020 10-K 14 Feb 2023 2022 FY
Q3 2020 $20,929,000 $6,470,000 +$3,135,000 +94% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $17,794,000 $6,373,000 +$3,041,000 +91% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $14,753,000 $4,675,000 +$1,629,000 +53% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $13,124,000 $3,411,000 01 Oct 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
Q3 2019 $3,335,000 +$782,000 +31% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $3,332,000 +$884,000 +36% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $3,046,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q3 2018 $2,553,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $2,448,000 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019 2019 Q2

Adaptive Biotechnologies Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $53,610,000 -$9,298,000 -15% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $62,908,000 +$7,431,000 +13% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $55,477,000 +$12,226,000 +28% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $43,251,000 +$18,490,000 +75% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $24,761,000 +$11,637,000 +89% 01 Jan 2020 31 Dec 2020 10-K 14 Feb 2023 2022 FY
2019 $13,124,000 +$1,975,000 +18% 01 Jan 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
2018 $11,149,000 +$4,140,000 +59% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $7,009,000 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.